Scholarlink

Background <p>Necrotizing enterocolitis (NEC) is a severe inflammatory gastrointestinal disease in neonates. We aimed to evaluate the potential of IgG anti-tissue transglutaminase antibodies (IgG tTG) as early biomarkers for NEC.</p> Method <p>We conducted a prospective observational study, collecting plasma from 60 neonates with abdominal distension (AD), which were divided into the NEC (<i>n</i> = 30) and the controls (<i>n</i> = 30) according to the follow-up results, and used the autoantigen microarray to identify for NEC-associated autoantibodies. An Enzyme-linked immunosorbent assay (ELISA) was utilized to measure plasma IgG tTG levels in a validation study (NEC <i>n</i> = 43, controls <i>n</i> = 20).</p> Results <p>Microarray analysis indicated significantly elevated IgG tTG levels in neonates with NEC compared to controls (<i>P</i> &lt; 0.001). ELISA further confirmed the significant elevation of IgG tTG in neonates with NEC (<i>P</i> &lt; 0.001). IgG tTG effectively distinguished neonates with NEC from the controls, with an area under the curve (AUC) of 0.8674 (sensitivity of 72.09% and specificity of 95%). Encouragingly, IgG tTG levels were significantly higher in neonates with NEC I than in controls (<i>P</i> &lt; 0.001). Additionally, as clinical conditions of neonates with NEC improved, the IgG tTG levels declined (<i>P</i> = 0.0159).</p> Conclusion <p>IgG tTG has potential as a biomarker for early diagnosis of NEC and predicting its prognosis after treatment.</p> Impact <p><UnorderedList Mark="Bullet"> <ItemContent> <p>Our results demonstrate that IgG anti-tissue transglutaminase antibodies possess significant diagnostic value for NEC.</p> </ItemContent> <ItemContent> <p>IgG anti-tissue transglutaminase antibodies can serve as a biomarker for early diagnosis NEC and its prognosis of treatment.</p> </ItemContent> <ItemContent> <p>The relationship between IgG anti-tissue transglutaminase antibodies and immune diseases may shed light on the pathogenesis of NEC, potentially opening new therapeutic avenues for preventing and treating neonates with NEC.</p> </ItemContent> </UnorderedList></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Necrotizing enterocolitis: diagnosis with plasma IgG anti-tissue transglutaminase antibodies

  • 期刊论文

  • 发表日期：

    2025年4月15日

查看全文
  • Hua Li,
  • Chaoting Lan,
  • Shuo Chen,
  • Chun Yan,
  • Shuchen Huangfu,
  • Bowen Tian,
  • Lin Li,
  • Yide Mu,
  • Shenwei Huang,
  • Jiemei Liang,
  • Liqiong Zhu,
  • Junjian Lv,
  • Yufeng Liu,
  • Yan Tian

摘要

Background

Necrotizing enterocolitis (NEC) is a severe inflammatory gastrointestinal disease in neonates. We aimed to evaluate the potential of IgG anti-tissue transglutaminase antibodies (IgG tTG) as early biomarkers for NEC.

Method

We conducted a prospective observational study, collecting plasma from 60 neonates with abdominal distension (AD), which were divided into the NEC (n = 30) and the controls (n = 30) according to the follow-up results, and used the autoantigen microarray to identify for NEC-associated autoantibodies. An Enzyme-linked immunosorbent assay (ELISA) was utilized to measure plasma IgG tTG levels in a validation study (NEC n = 43, controls n = 20).

Results

Microarray analysis indicated significantly elevated IgG tTG levels in neonates with NEC compared to controls (P < 0.001). ELISA further confirmed the significant elevation of IgG tTG in neonates with NEC (P < 0.001). IgG tTG effectively distinguished neonates with NEC from the controls, with an area under the curve (AUC) of 0.8674 (sensitivity of 72.09% and specificity of 95%). Encouragingly, IgG tTG levels were significantly higher in neonates with NEC I than in controls (P < 0.001). Additionally, as clinical conditions of neonates with NEC improved, the IgG tTG levels declined (P = 0.0159).

Conclusion

IgG tTG has potential as a biomarker for early diagnosis of NEC and predicting its prognosis after treatment.

Impact

Our results demonstrate that IgG anti-tissue transglutaminase antibodies possess significant diagnostic value for NEC.

IgG anti-tissue transglutaminase antibodies can serve as a biomarker for early diagnosis NEC and its prognosis of treatment.

The relationship between IgG anti-tissue transglutaminase antibodies and immune diseases may shed light on the pathogenesis of NEC, potentially opening new therapeutic avenues for preventing and treating neonates with NEC.